Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab

Thomas E. Witzig; David J. Inwards; Thomas M. Habermann; Ahmet Dogan; Paul J. Kurtin; John B. Gross; Anuradha Ananthamurthy; Kay M. Ristow; James A. Garrity

doi:10.4065/82.6.692

Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab

Thomas E. Witzig, David J. Inwards, Thomas M. Habermann, Ahmet Dogan, Paul J. Kurtin, John B. Gross, Anuradha Ananthamurthy, Kay M. Ristow, James A. Garrity

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

OBJECTIVE: To report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab. PATIENTS AND METHODS: Patients were included in the study if they had an orbital mass and biopsy-proven orbital pseudolymphomas between January 1, 1998, and December 31, 2005. The study focused on patients treated with rituximab. RESULTS: Ninety-eight patients were evaluated, and the biopsy results revealed malignant non-Hodgkin lymphoma in 72 (73%); the other 26 (27%) had a pseudolymphoma. Eleven (42%) of the 26 patients with a pseudolymphoma were treated with rituximab, 375 mg/m², intravenously each week for 4 doses, and 10 (91%) of the 11 responded. Seven patients were either treated with maintenance rituximab or successfully retreated with rituximab after relapse. None of the 10 responders has become refractory to rituximab. CONCLUSION: Benign lymphoproliferative tumors are responsive to monoclonal antibody therapy targeted to B lymphocytes. Rituximab should be considered a treatment option for orbital pseudolymphomas.

Original language	English (US)
Pages (from-to)	692-699
Number of pages	8
Journal	Mayo Clinic proceedings
Volume	82
Issue number	6
DOIs	https://doi.org/10.4065/82.6.692
State	Published - Jun 2007

ASJC Scopus subject areas

General Medicine

Access to Document

10.4065/82.6.692

Cite this

@article{f8fd63096e0240d7be55a32e840ab632,

title = "Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab",

abstract = "OBJECTIVE: To report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab. PATIENTS AND METHODS: Patients were included in the study if they had an orbital mass and biopsy-proven orbital pseudolymphomas between January 1, 1998, and December 31, 2005. The study focused on patients treated with rituximab. RESULTS: Ninety-eight patients were evaluated, and the biopsy results revealed malignant non-Hodgkin lymphoma in 72 (73%); the other 26 (27%) had a pseudolymphoma. Eleven (42%) of the 26 patients with a pseudolymphoma were treated with rituximab, 375 mg/m2, intravenously each week for 4 doses, and 10 (91%) of the 11 responded. Seven patients were either treated with maintenance rituximab or successfully retreated with rituximab after relapse. None of the 10 responders has become refractory to rituximab. CONCLUSION: Benign lymphoproliferative tumors are responsive to monoclonal antibody therapy targeted to B lymphocytes. Rituximab should be considered a treatment option for orbital pseudolymphomas.",

author = "Witzig, {Thomas E.} and Inwards, {David J.} and Habermann, {Thomas M.} and Ahmet Dogan and Kurtin, {Paul J.} and Gross, {John B.} and Anuradha Ananthamurthy and Ristow, {Kay M.} and Garrity, {James A.}",

year = "2007",

month = jun,

doi = "10.4065/82.6.692",

language = "English (US)",

volume = "82",

pages = "692--699",

journal = "Mayo Clinic proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "6",

}

TY - JOUR

T1 - Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab

AU - Witzig, Thomas E.

AU - Inwards, David J.

AU - Habermann, Thomas M.

AU - Dogan, Ahmet

AU - Kurtin, Paul J.

AU - Gross, John B.

AU - Ananthamurthy, Anuradha

AU - Ristow, Kay M.

AU - Garrity, James A.

PY - 2007/6

Y1 - 2007/6

N2 - OBJECTIVE: To report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab. PATIENTS AND METHODS: Patients were included in the study if they had an orbital mass and biopsy-proven orbital pseudolymphomas between January 1, 1998, and December 31, 2005. The study focused on patients treated with rituximab. RESULTS: Ninety-eight patients were evaluated, and the biopsy results revealed malignant non-Hodgkin lymphoma in 72 (73%); the other 26 (27%) had a pseudolymphoma. Eleven (42%) of the 26 patients with a pseudolymphoma were treated with rituximab, 375 mg/m2, intravenously each week for 4 doses, and 10 (91%) of the 11 responded. Seven patients were either treated with maintenance rituximab or successfully retreated with rituximab after relapse. None of the 10 responders has become refractory to rituximab. CONCLUSION: Benign lymphoproliferative tumors are responsive to monoclonal antibody therapy targeted to B lymphocytes. Rituximab should be considered a treatment option for orbital pseudolymphomas.

AB - OBJECTIVE: To report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab. PATIENTS AND METHODS: Patients were included in the study if they had an orbital mass and biopsy-proven orbital pseudolymphomas between January 1, 1998, and December 31, 2005. The study focused on patients treated with rituximab. RESULTS: Ninety-eight patients were evaluated, and the biopsy results revealed malignant non-Hodgkin lymphoma in 72 (73%); the other 26 (27%) had a pseudolymphoma. Eleven (42%) of the 26 patients with a pseudolymphoma were treated with rituximab, 375 mg/m2, intravenously each week for 4 doses, and 10 (91%) of the 11 responded. Seven patients were either treated with maintenance rituximab or successfully retreated with rituximab after relapse. None of the 10 responders has become refractory to rituximab. CONCLUSION: Benign lymphoproliferative tumors are responsive to monoclonal antibody therapy targeted to B lymphocytes. Rituximab should be considered a treatment option for orbital pseudolymphomas.

UR - http://www.scopus.com/inward/record.url?scp=34249936959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249936959&partnerID=8YFLogxK

U2 - 10.4065/82.6.692

DO - 10.4065/82.6.692

M3 - Article

C2 - 17550749

AN - SCOPUS:34249936959

SN - 0025-6196

VL - 82

SP - 692

EP - 699

JO - Mayo Clinic proceedings

JF - Mayo Clinic proceedings

IS - 6

ER -

Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this